Gdynia, Poland Clinical Trials

A listing of Gdynia, Poland clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 105 clinical trials
Phase 3 Randomized Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-LUNG01)

This study will evaluate the efficacy, safety, and pharmacokinetics of DS-1062a versus docetaxel in participants with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations.

RET
epidermal growth factor
epidermal growth factor receptor
BRAF
NTRK
Szpitale Pomorskie Sp.zo.o
 (2.2 away) Contact site
  • 0 views
  • 24 Oct, 2022
  • +184 other locations
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression (FORTITUDE-101)

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS).

leucovorin
neutrophil count
platelet count
cancer chemotherapy
measurable disease
Szpitale Pomorskie Spzoo
 (2.2 away) Contact site
  • 0 views
  • 21 Oct, 2022
  • +166 other locations
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

lung cancer
paclitaxel
stage iii non-small cell lung cancer
pemetrexed
stage iv non-small cell lung cancer
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2400)
 (2.2 away) Contact site
  • 253 views
  • 21 Oct, 2022
  • +163 other locations
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) (BRUIN CLL-321)

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and …

rituximab
bendamustine
chronic lymphocytic leukemia
idelalisib
neutrophil count
Szpitale Pomorskie Sp. z o. o.
 (2.4 away) Contact site
  • 5 views
  • 22 Oct, 2022
  • +207 other locations
Induction Study #2 - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.

abdominal pain
endoscopy
immunomodulators
corticosteroids
ileal disease
Local Institution - 577
 (1.7 away) Contact site
  • 550 views
  • 22 Oct, 2022
  • +356 other locations
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease

This is a study to demonstrate the effect of oral ozanimod as maintenance therapy in participants with moderately to severely active Crohn's Disease.

abdominal pain
crohn's disease
remission
Endoskopia Sp. z o.o.
 (5.6 away) Contact site
  • 1028 views
  • 22 Oct, 2022
  • +489 other locations
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease (VIVID-2)

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

crohn's disease
Synexus Polska Sp. z o.o. Oddzial w Gdyni
 (0.6 away) Contact site
  • 47 views
  • 24 Oct, 2022
  • +281 other locations
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Crohn's Disease

The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.

enteropathy
crohn's disease
Endoskopia
 (5.6 away) Contact site
  • 372 views
  • 24 Oct, 2022
  • +209 other locations
EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel Group, Double-blind Placebo-controlled Superiority Trial to Evaluate the Effect of EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With aCuTe Myocardial Infarction

This is a study in adults who had a heart attack (myocardial infarction). The purpose of this study is to find out whether a medicine called empagliflozin helps to lower the chances of having to go to the hospital for heart failure and whether it lowers the chances of dying …

angiography
cardiovascular disease
acute myocardial infarction
heart failure
st elevation myocardial infarction
NZOZ Pro-Cordis Sopockie Centrum Bad. Kardiolog.
 (1.0 away) Contact site
  • 204 views
  • 24 Oct, 2022
  • +436 other locations
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Patients With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

This Phase III, randomized, double-blind, placebo-controlled, multicenter study will evaluate the efficacy and safety of giredestrant combined with palbociclib compared with letrozole combined with palbociclib in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2)-negative locally advanced (recurrent or progressed) or metastatic breast cancer.

Szpital Morski im. PCK; Poradnia Onkologiczna
 (2.2 away) Contact site
  • 1 views
  • 24 Oct, 2022
  • +292 other locations